Development and characterization of liposomal formulation of bortezomib

Bortezomib is a proteasome inhibitor used for the treatment of multiple myeloma. The poor pharmacokinetic profile and off-target adverse effects provide a strong incentive to develop drug delivery systems for bortezomib. In the past, liposomal encapsulation has been proven to improve the therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshantri, Anil K., Metselaar, Josbert M., Zagkou, Stavroula, Storm, Gert, Mandhane, Sanjay N., Fens, Marcel H.A.M., Schiffelers, Raymond M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733293/
https://www.ncbi.nlm.nih.gov/pubmed/31517276
http://dx.doi.org/10.1016/j.ijpx.2019.100011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733293/
https://www.ncbi.nlm.nih.gov/pubmed/31517276
http://dx.doi.org/10.1016/j.ijpx.2019.100011

Ejemplares similares